- Home
- BSTZ vs CVAC Comparison
BSTZ vs CVAC Comparison
Compare BSTZ & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSTZ
- CVAC
- Stock Information
- Founded
- BSTZ 2019
- CVAC 2000
- Country
- BSTZ United States
- CVAC Germany
- Employees
- BSTZ N/A
- CVAC N/A
- Industry
- BSTZ Trusts Except Educational Religious and Charitable
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- BSTZ Finance
- CVAC Health Care
- Exchange
- BSTZ Nasdaq
- CVAC Nasdaq
- Market Cap
- BSTZ 1.4B
- CVAC 1.2B
- IPO Year
- BSTZ N/A
- CVAC 2020
- Fundamental
- Price
- BSTZ $21.44
- CVAC $5.47
- Analyst Decision
- BSTZ
- CVAC Hold
- Analyst Count
- BSTZ 0
- CVAC 3
- Target Price
- BSTZ N/A
- CVAC $6.83
- AVG Volume (30 Days)
- BSTZ 303.2K
- CVAC 822.3K
- Earning Date
- BSTZ 01-01-0001
- CVAC 08-14-2025
- Dividend Yield
- BSTZ 8.31%
- CVAC N/A
- EPS Growth
- BSTZ N/A
- CVAC N/A
- EPS
- BSTZ 0.71
- CVAC 0.87
- Revenue
- BSTZ N/A
- CVAC $566,039,775.00
- Revenue This Year
- BSTZ N/A
- CVAC N/A
- Revenue Next Year
- BSTZ N/A
- CVAC $24.04
- P/E Ratio
- BSTZ $26.69
- CVAC $6.32
- Revenue Growth
- BSTZ N/A
- CVAC 787.60
- 52 Week Low
- BSTZ $14.11
- CVAC $2.37
- 52 Week High
- BSTZ $19.43
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- BSTZ 68.27
- CVAC 60.72
- Support Level
- BSTZ $20.89
- CVAC $5.35
- Resistance Level
- BSTZ $21.47
- CVAC $5.48
- Average True Range (ATR)
- BSTZ 0.26
- CVAC 0.05
- MACD
- BSTZ -0.02
- CVAC -0.03
- Stochastic Oscillator
- BSTZ 96.74
- CVAC 82.76
About BSTZ BlackRock Science and Technology Term Trust of Beneficial Interest
BlackRock Science and Technology Trust II is a non-diversified, closed-end management investment company. The trust's investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation. Its portfolio consists of Equity Securities, Options, Preferred Securities, Convertible Securities, Depositary Receipts, Non-U.S. Securities, Emerging Markets Investments, Restricted and Illiquid Investments, Private Company Investments, Corporate Bonds, and other investments. The trust seeks to Invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. science and technology companies in any market capitalization range from the development, advancement, and use of science and/or technology.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.